Moreover, subsequent studies showed that the percentage of ERBB4-mutated samples was indeed much lower in an independent cohort (around 3%), and the higher percentage found in the first study might have been due to a sampling bias of melanoma cell cultures versus melanoma tissues [41]. The gene discussed is ERBB4; the disease is melanoma.